CHM — Chimeric Therapeutics Balance Sheet
0.000.00%
- AU$7.88m
- AU$5.32m
Annual balance sheet for Chimeric Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | R2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 0 | 22.4 | 18.4 | 2.36 | 3.05 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 0.024 | 2.66 | 6.66 | 0.087 |
Total Other Current Assets | |||||
Total Current Assets | 0 | 22.7 | 21.2 | 9.35 | 3.22 |
Net Property, Plant And Equipment | — | 0.014 | 0.016 | 0.006 | 0.001 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 0 | 36.5 | 34.9 | 22.4 | 15.3 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.064 | 7.35 | 9.02 | 14.7 | 10.1 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.064 | 11.4 | 9.17 | 16.7 | 12.8 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -0.064 | 25.1 | 25.7 | 5.66 | 2.47 |
Total Liabilities & Shareholders' Equity | 0 | 36.5 | 34.9 | 22.4 | 15.3 |
Total Common Shares Outstanding |